Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emtricitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | POLG | P54098 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.63 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.63 |
| ▸ | DCK | P27707 | 7/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emtricitabine, (+/-)- SCHEMBL122131 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL267686 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3230512 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12202574 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL6903677 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL5427218 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL6362885 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL3722124 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL22413085 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT | |
| Emtricitabine SCHEMBL12662838 | 1.00 | ALB (1.00) | ALBPOLGLMNACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28406 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4746907-A1 | METHOD OF TREATMENT OF HIV INFECTION WITH VACCINE | Gilead Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260137622-A1 | PHARMACEUTICAL FORMULATIONS | GILEAD SCIENCES INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137623-A1 | Pharmaceutical Formulations Comprising Tenofovir Alafenamide And Emtricitabine | GILEAD SCIENCES INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629338-B1 | Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine | GILEAD SCIENCES, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-3852761-B1 | AN ADMINISTRATION REGIMEN OF INTEGRASE INHIBITORS FOR PREVENTING HIV INFECTION BY POST-EXPOSURE PROPHYLAXIS | GILEAD SCIENCES INC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| US-5827727-A | ENZYMATIC STEREOSPECIFIC HYDROLYSIS OF 5-O-ACYLATED NUCLEOSIDE BY AN ESTERASE, LIPASE, OR SUBTILISIN | EMORY UNIVERSITY (US) | 1998-10-27 | — | — | US | claimed |
| EP-0817637-A1 | SYNERGISTIC COMBINATIONS OF ZIDOVUDINE, 1592U89 AND 3TC OR FTC | THE WELLCOME FOUNDATION LIMITED (GB) | 1998-01-14 | — | — | EP | claimed |
| WO-1997049411-A1 | COMBINATIONS COMPRISING VX478, ZIDOVUDINE, FTC AND/OR 3TC FOR USE IN THE TREATMENT OF HIV | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | claimed |
| US-5618820-A | (-)CIS-4-AMINO-5-FLUORO-1-(2-HYDROXYMETHYL-1,3-OXATHIOLAN-5 YL-(1H)-PYRIMIDINE-2-ONE OR SALT OR ESTER; ADMINISTERING TO TREAT VIRAL INFECTION IN A MAMMAL | BIOCHEM PHARMA, INC. (CA) | 1997-04-08 | — | — | US | claimed |
| WO-1996030025-A1 | SYNERGISTIC COMBINATIONS OF ZIDOVUDINE, 1592U89 AND 3TC OR FTC | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-10-03 | — | — | WO | claimed |
| US-5538975-A | (-)-4-AMINO-5-FLUORO-1-(2-HYDROXYMETHYL-1,3-OXATHIOLAN-5YL) -(1H)-PYRIMIDIN-2-ONE AND DERIVATIVES; ANTIVIRAL AGENT | BIOCHEM PHARMA, INC. (CA) | 1996-07-23 | — | — | US | claimed |
| EP-0574487-A1 | USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-22 | — | — | EP | claimed |
| US-5234913-A | Synergistic mixture of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocystosine and zidovudine | BURROUGHS WELLCOME CO. (US) | 1993-08-10 | — | — | US | claimed |
| US-5210085-A | Treating HIV infections | EMORY UNIVERSITY (US) | 1993-05-11 | — | — | US | claimed |
| WO-1992015308-A1 | USE OF 5-FLUORO-2'-DEOXY-3'-THIACYTIDINE FOR THE TREATMENT OF HEPATITIS B | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |